OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients
Status:
Completed
Trial end date:
2015-07-10
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, single-dose, parallel group study. The objectives of this
study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN)
prolonged release (PR) tablet 5/2.5 mg (OXN 5/2.5) and 20/10 mg (OXN 20/10) in Chinese
patients with moderate to severe chronic non-malignant pain.